Close

Research Grade (RG) CAR-T Virus Manufacturing Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The effectiveness of CAR-T therapy heavily relies on the quality and consistency of the viral vectors used for T-cell modification. This necessitates high-quality, Research Grade (RG) virus manufacturing processes to ensure the safety, efficacy, and reproducibility of these therapeutic products. At Creative Biolabs, we focus on delivering cutting-edge virus manufacturing services specifically designed for CAR-T therapy. Our state-of-the-art facilities and experienced team leverage cutting-edge technologies to produce high-quality viral vectors, ensuring optimal transduction efficiency and safety for CAR-T cell therapies.

Why Do Research Grade (RG) Virus Manufacturing

  • RG viruses are produced under more controlled conditions than standard laboratory-grade viruses, ensuring higher quality and purity.
  • RG products are usually subjected to stringent safety measures to minimize risks associated with viral contaminants or unpredictable biological activity.
  • Using RG viruses allows for standardization of experimental procedures, making it easier to compare results across different studies or laboratories.
  • Using RG virus can help meet regulatory guidelines and prepare for eventual Good Manufacturing Practice (GMP) compliance.

Fig.1 Expression systems.Fig.1 Expression systems for different viral vectors.1

Our Service

Our RG Virus Manufacturing for CAR-T cell therapy service offers a comprehensive solution for researchers and companies looking to produce high-quality viral vectors essential for gene delivery and cell modification. Utilizing state-of-the-art facilities and cutting-edge technologies, we ensure the production of replication-incompetent lentiviruses and other viral vectors that meet stringent regulatory and quality standards. Our team of experienced scientists provides tailored services, from the initial design phase through to the final product, guaranteeing robust titers and purity levels that enhance the efficiency of your CAR-T research. With a commitment to transparency and collaboration, we facilitate every step of the process, enabling clients to focus on their innovative work while we handle the complexities of virus manufacturing.

Fig.2 Advantages. (Creative Biolabs Original)

Manufacturing Process

Our manufacturing process of RG virus for CAR T-cell therapy involves several meticulously controlled steps to ensure the production of high-quality viral vectors, essential for effective gene transfer. Initially, the process begins with the selection of appropriate plasmids that encode the desired CAR and any necessary viral packaging components. The plasmids are then transfected into a suitable producer cell line, often HEK293 cells, using calcium phosphate or lipid-based transfection methods. Following transfection, the cells are cultured in bioreactors under optimized conditions to facilitate viral assembly and release. Once sufficient viral titers are achieved, the supernatant is harvested and subjected to purification processes, including filtration and chromatography, to remove impurities and isolate the RG virus. Subsequently, the purified virus is characterized through techniques such as titer determination, quality control assays, and sequencing to ensure the absence of contamination and verify the integrity of the viral genome. Finally, the RG virus is formulated for storage and distribution, ensuring compliance with regulatory standards for research use.

Fig.3 Process. (Creative Biolabs Original)

More Global CDMO Services for CAR Viral Vector, please click here!

Research Grade vs. Clinical Grade (CG)

  • RG viruses are produced for research purposes, allowing for experiments and preclinical trials.
  • They are distinct from CG vectors, which are produced under Good Manufacturing Practice (GMP) conditions for human applications.
  • RG vectors may not fulfill the rigorous safety and quality standards mandated for clinical use.

Contact Us

Ready to elevate your CAR-T therapy projects with our expert virus manufacturing services? Creative Biolabs' committed team is ready to assist you! For any inquiries, customized quotes, or to discuss your specific project needs, please contact us today! By partnering with us, you can expect reliable, scalable, and customized solutions to meet your specific research and clinical needs, empowering the next generation of breakthrough treatments for cancer and other diseases.

Reference

  1. Lundstrom, Kenneth. "Viral Vectors in Gene Therapy: Where Do We Stand in 2023?." Viruses vol. 15,3 698. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.